

Avon Lifesciences Limited (Formerly Avon Organics Limited)

CIN: L24110TG1993PLC016112

Regd. Off:- Survey No.18, Yawapur Village, Sadasivpet Mandal, Medak District, Telangana - 502 291
Corp. Off: H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai - 400072
Web site: -www.avonlifesciences.com, E-mail: info@avonlifesciences.com, Tel: 022-2803-7777

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED ON 31st DECEMBER, 2015

(Rs. in Lakhs)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31-Dec-15	30-Sep-15	31-Dec-14	31-Dec-15	31-Dec-14	31-Mar-15
	Unaudited			Unaudited		Audited
1 Revenue From Operations						
Net sales or Revenue from Operations	556.44	1429.30	23.36	3198.45	1161.50	2905.50
Other operating revenues	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue from operations (net)	556.44	1429.30	23.36	3198.45	1161.50	2905.50
2 Expenses						
(a) Cost of materials consumed	57.57	236.04	0.00	633.69	1046.18	2671.01
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	467.43	330.10	34.38	994.13	179.73	178.41
(d) Employee benefit expense	96.04	116.33	122.15	300.59	431.77	617.37
(e) Depreciation and amortisation expense	104.79	103.79	230.13	311.28	688.14	777.73
(f) Other Expenses	148.37	194.88	34.28	415.92	111.99	431.70
(g) Exchange rate (Gain) / Loss	0.00	0.00	0.00	0.00	0.00	(47.23)
Total expenses	874.20	981.14	420.94	2655.61	2,457.81	4,628.99
3 Profit (loss) from operations before other income, finance costs and exceptional items	(317.76)	448.16	(397.58)	542.84	(1,296.31)	(1,723.48)
4 Other income	0.53	2.83	0.00	6.28	2.55	5.98
5 Profit (loss) from ordinary activities before finance costs and exceptional items	(317.23)	450.99	(397.58)	549.12	(1,293.76)	(1,717.50)
6 Finance costs	425.54	267.75	387.76	1075.51	1174.00	1561.86
7 Profit (loss) from ordinary activities after finance costs but before exceptional items	(742.77)	183.24	(785.34)	(526.39)	(2,467.76)	(3,279.37)
8 Exceptional items	0.000	0.00	0.00	0.00	0.00	253.77
9 Profit (loss) from ordinary activities before tax	(742.77)	183.24	(785.34)	(526.39)	(2,467.76)	(3,025.60)
10 Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00
11 Net profit (loss) from ordinary activities after tax	(742.77)	183.24	(785.34)	(526.39)	(2,467.76)	(3,025.60)
12 Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
13 Net profit (loss) for the period	(742.77)	183.24	(785.34)	(526.39)	(2,467.76)	(3,025.60)
14 Share of profit (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15 Profit (loss) of minority interest	0.00	0.00	0.00	0.00	0.00	0.00
16 Net Profit (loss) after taxes minority interest and share of profit (loss) of associates	(742.77)	183.24	(785.34)	(526.39)	(2,467.76)	(3,025.60)
17 Details of equity share capital						
Paid-up equity share capital	2372.50	2250.00	2250.00	2372.50	2250.00	2250.00
Face value of equity share capital (inRs.)	10.00	10.00	10.00	10.00	10.00	10.00
18 Reserves excluding revaluation reserve	0.00	0.00	0.00	0.00	0.00	0.00
19 Earnings per share						
i Earnings per share before extraordinary items						
Basic earnings per share before extraordinary items (Not Annualised) (inRs.)	(3.30)	0.81	(3.49)	(2.34)	(10.97)	(13.45)
Diluted earnings per share before extraordinary items (Not Annualised) (inRs.)	(3.03)	0.81	(3.49)	(2.15)	(10.97)	(13.45)
ii Earnings per share after extraordinary items						
Basic earnings per share after extraordinary items (inRs.)	(3.30)	0.81	(3.49)	(2.34)	(10.97)	(13.45)
Diluted earnings per share after extraordinary items (inRs.)	(3.03)	0.81	(3.49)	(2.15)	(10.97)	(13.45)
Part II						
1 Public share holding						
Number of shares of held by public	13015900	11790900	8190900	13015900	8190900	11490900
Percentage of shareholding held by public	54.86%	52.40%	36.40%	54.86%	36.40%	51.07%
2 Promoters and promoters group shareholding [abstract]						
(a) Details of pledged or encumbered shares						
Pledged/Encumbered - Number of shares	0	0	0	0	0	0
Pledged/Encumbered - Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0	0	0
Pledged/Encumbered - Percentage of shares (as a % of the total share capital of the company)	0	0	0	0	0	0
(b) Details of non-encumbered shares						
Non-encumbered - Number of Shares	10709100	10709100	14309100	10,709,100	14309100	11009100
Non-encumbered - Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Non-encumbered - Percentage of shares (as a % of the total share capital of the company)	45.14%	47.60%	63.60%	45.14%	63.60%	48.93%
B Investor Complaints						
Pending at the beginning of the quarter	0					
Received during the quarter	1					
Disposed of during the quarter	1					
Remaining unresolved at the end of the quarter	0					

Note:

- Above results have been reviewed by audit committee and approved by the Board of Directors at their meeting held on February 12, 2016
- Statutory Auditors have carried out Limited Review of above results
- The company operates exclusively in one reportable business segment, "Pharmaceuticals". There are no extra ordinary items.
- Previous period figures have been regrouped whenever necessary

Date: 12-02-2016
Place: Mumbai



For Avon Lifesciences Limited

Ajit Kamath
Chairman



Limited Review Report

**To the Board of Directors
Avon Lifesciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Avon Lifesciences Limited ('the Company') for the three months and nine months period ended 31st December 2015. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards as per section 133 of the Companies Act 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. Mukesh Mehta & Associates
CHARTERED ACCOUNTANTS


Mukesh Mehta

Proprietor

Firm Reg. No. 116309W

M. No. 100407



Date: February 12, 2016

Place: Mumbai